DK1027339T3 - Fremgangsmåde og reagenser til N-alkylering af ureider - Google Patents

Fremgangsmåde og reagenser til N-alkylering af ureider

Info

Publication number
DK1027339T3
DK1027339T3 DK98949706T DK98949706T DK1027339T3 DK 1027339 T3 DK1027339 T3 DK 1027339T3 DK 98949706 T DK98949706 T DK 98949706T DK 98949706 T DK98949706 T DK 98949706T DK 1027339 T3 DK1027339 T3 DK 1027339T3
Authority
DK
Denmark
Prior art keywords
ureas
alkylation
reagents
methoxymethyl
diphenylbarbituric
Prior art date
Application number
DK98949706T
Other languages
English (en)
Inventor
Daniela Gutman
Hershel Herzog
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Application granted granted Critical
Publication of DK1027339T3 publication Critical patent/DK1027339T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4042,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86Oxygen atoms
    • C07D211/88Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72Two oxygen atoms, e.g. hydantoin
    • C07D233/74Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • C07D239/62Barbituric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
DK98949706T 1997-10-02 1998-10-02 Fremgangsmåde og reagenser til N-alkylering af ureider DK1027339T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/942,636 US6093820A (en) 1997-10-02 1997-10-02 Method and reagents for N-alkylating ureides
PCT/US1998/020665 WO1999018084A1 (en) 1997-10-02 1998-10-02 Method and reagents for n-alkylating ureides

Publications (1)

Publication Number Publication Date
DK1027339T3 true DK1027339T3 (da) 2004-05-03

Family

ID=25478386

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03011817T DK1342718T3 (da) 1997-10-02 1998-10-02 N-alkylerede ureider
DK98949706T DK1027339T3 (da) 1997-10-02 1998-10-02 Fremgangsmåde og reagenser til N-alkylering af ureider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03011817T DK1342718T3 (da) 1997-10-02 1998-10-02 N-alkylerede ureider

Country Status (13)

Country Link
US (4) US6093820A (da)
EP (2) EP1027339B1 (da)
JP (2) JP4061018B2 (da)
CN (2) CN1193019C (da)
AT (2) ATE257153T1 (da)
AU (1) AU758506B2 (da)
CA (1) CA2304970C (da)
DE (2) DE69820895T2 (da)
DK (2) DK1342718T3 (da)
ES (2) ES2214736T3 (da)
IL (2) IL135284A (da)
PT (2) PT1342718E (da)
WO (1) WO1999018084A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (en) * 2002-01-30 2006-04-12 Taro Pharma Ind NON-SURFACTANT BARBITIC ACID DERIVATIVES
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2315569T3 (es) * 2002-12-11 2009-04-01 Taro Pharmaceutical Industries Ltd. Procedimiento de tratamiento de trastornos del movimiento usando derivados de acido barbiturico.
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8853257B2 (en) 2005-11-21 2014-10-07 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
WO2007057889A2 (en) * 2005-11-21 2007-05-24 Mordechai Sharir Succinimide derivatives as ocular hypotensive agents
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
SG190037A1 (en) 2010-10-27 2013-06-28 Gillette Co Composition dispensing device comprising a non-foaming hydrating composition
US20120278179A1 (en) * 2011-04-28 2012-11-01 Ray Campbell Systems and methods for deducing user information from input device behavior
BR112014003344A2 (pt) 2011-08-16 2017-01-17 Gillette Co dispositivo dispensador de composição compreendendo uma composição umectante
SG11201602439RA (en) 2013-11-01 2016-04-28 Gillette Co Shave care composition for a liquid dispensing razor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
AR204518A1 (es) * 1973-02-28 1976-02-12 Kendall & Co Procedimiento para preparar n-mono(alcoximetil)fenobarbital
DE2622981A1 (de) * 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4028040A1 (de) * 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
WO1998029408A1 (en) 1996-12-26 1998-07-09 Nikken Chemicals Co., Ltd. N-hydroxyurea derivatives and medicinal compositions containing the same
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US6372757B1 (en) 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
EP1083172A4 (en) 1998-05-26 2001-10-10 Rimma Iliinichna Ashkinazi N-SUBSTITUTED DERIVATIVES OF 5-OXYIMINOBARBITURIC ACID
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
DE60132337T2 (de) 2000-07-26 2009-02-12 Taro Pharmaceutical Industries Ltd. Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Also Published As

Publication number Publication date
US6093820A (en) 2000-07-25
CN1193019C (zh) 2005-03-16
PT1027339E (pt) 2004-05-31
AU758506B2 (en) 2003-03-20
EP1027339A1 (en) 2000-08-16
ATE299500T1 (de) 2005-07-15
US6664262B2 (en) 2003-12-16
JP2001519334A (ja) 2001-10-23
CA2304970A1 (en) 1999-04-15
DE69830860T2 (de) 2006-04-27
AU9597698A (en) 1999-04-27
PT1342718E (pt) 2005-11-30
ES2214736T3 (es) 2004-09-16
DE69820895D1 (de) 2004-02-05
US20040167358A1 (en) 2004-08-26
EP1342718A1 (en) 2003-09-10
US20030018080A1 (en) 2003-01-23
DK1342718T3 (da) 2005-09-26
JP4061018B2 (ja) 2008-03-12
ATE257153T1 (de) 2004-01-15
WO1999018084A1 (en) 1999-04-15
EP1027339B1 (en) 2004-01-02
DE69820895T2 (de) 2004-10-28
CN1699349A (zh) 2005-11-23
US6906079B2 (en) 2005-06-14
CA2304970C (en) 2010-07-13
IL165080A0 (en) 2005-12-18
EP1342718B1 (en) 2005-07-13
DE69830860D1 (de) 2005-08-18
USRE38934E1 (en) 2006-01-10
JP2008101002A (ja) 2008-05-01
IL135284A (en) 2005-11-20
CN1273581A (zh) 2000-11-15
ES2243833T3 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
DK1027339T3 (da) Fremgangsmåde og reagenser til N-alkylering af ureider
FI870113A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6-substioitujenN-(substituoitu-fenyyli)-2-pyrimidiiniamiinien valmistamiseksi
NO980255D0 (no) Antiparasittiske marcfortiner og paraherkvamider
NO994998D0 (no) Fusjonsproteiner
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
ATE373672T1 (de) Synthese von methoxynukleoside und enzymatische nukleisäure moleküle
IL149459A0 (en) Recombinant gelatins
NO20005153L (no) Mutantprotein som har lavere allergenisk respons i mennesker og fremgangsmåter for konstruksjon, identifisering og fremstilling av slike proteiner
NO20090583L (no) Terapi for alfa-galaktosidase A-mangel
DK0923978T3 (da) Fremgangsmåde til behandling af röggas
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
IS5542A (is) Tríazín efnasambönd til meðhöndlunar á truflunum í miðtaugakerfi (CNS)
DE69634077D1 (de) Haemophilus adhäsionsproteinen
DK0744027T3 (da) Anvendelse af fremgangsmåder til identifikation af hydrofile signaloligopeptider
DE69737457D1 (de) O-fukosyltransferase
DK0862939T3 (da) Fremgangsmåde til behandling af röggas
DE69938144D1 (de) Antikörper-vermittelte verminderungsregulation von pflanzenproteinen
DK1086114T3 (da) Morfin-6-glucuronidsyntese
CY1109583T1 (el) Κυτοκινες θηλαστικων, αντιστοιχα αντιδραστηρια
EA199800090A1 (ru) Способ получения 4,6-диметокси-2-((феноксикарбонил)амино)пиримидина
DE69802636D1 (de) Verbessertes Verfahren zur Herstellung von unsymmetrischen 4,6-bis(aryloxy)pyrimidinverbindungen
DK0593285T3 (da) Mellemprodukter og fremgangsmåder dertil til fremstilling af 5,6-dihydropyrrolo-(2,3-d)pyrimidiner
ATE265425T1 (de) Verfahren zur herstellung von n-(5-amino-2-cyano- 4-fluor-phenyl)-sulfonamiden
DK0414171T3 (da) Fremgangsmåde til enzymatisk syntese af galactosylerede glycoprotein-komponenter
DK0857720T3 (da) Fremgangsmåde til syntese af desoxypyridinolin